Amylyx Pharmaceuticals
Founded Year
2014Stage
IPO | IPOTotal Raised
$205.83MDate of IPO
1/7/2022Market Cap
1.27BStock Price
18.88About Amylyx Pharmaceuticals
Amylyx (NASDAQ: AMLX) is an IND-enabling stage biopharmaceutical company dedicated to providing disease-modifying solutions for neurodegenerative diseases. The company is focused on streamlined clinical development and drug discovery.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Amylyx Pharmaceuticals Patents
Amylyx Pharmaceuticals has filed 20 patents.
The 3 most popular patent topics include:
- Rare diseases
- Calcium channel blockers
- Motor neuron diseases
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
7/27/2020 | 2/21/2023 | Sugar substitutes, Bile acids, Cholanes, Hepatology, Excipients | Grant |
Application Date | 7/27/2020 |
|---|---|
Grant Date | 2/21/2023 |
Title | |
Related Topics | Sugar substitutes, Bile acids, Cholanes, Hepatology, Excipients |
Status | Grant |
Latest Amylyx Pharmaceuticals News
Sep 5, 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, will participate at two upcoming investor conferences on September 11-12.
Amylyx Pharmaceuticals Frequently Asked Questions (FAQ)
When was Amylyx Pharmaceuticals founded?
Amylyx Pharmaceuticals was founded in 2014.
Where is Amylyx Pharmaceuticals's headquarters?
Amylyx Pharmaceuticals's headquarters is located at 43 Thorndike Street, Cambridge.
What is Amylyx Pharmaceuticals's latest funding round?
Amylyx Pharmaceuticals's latest funding round is IPO.
How much did Amylyx Pharmaceuticals raise?
Amylyx Pharmaceuticals raised a total of $205.83M.
Who are the investors of Amylyx Pharmaceuticals?
Investors of Amylyx Pharmaceuticals include Belinda Termeer, Verition Fund Management, aMoon Fund, Woodline Partners, Perceptive Advisors and 19 more.
Who are Amylyx Pharmaceuticals's competitors?
Competitors of Amylyx Pharmaceuticals include OptoCeutics and 2 more.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Compare Amylyx Pharmaceuticals to Competitors
EnClear Therapies develops a treatment device to stop the progress of neurodegenerative diseases.
OptoCeutics develops medical light that can restore the neuronal activity of Alzheimer's patients and reduce plaque accumulation, which can lead to the development of new medical technologies. The technology is based on known gamma light therapy research, but combines the light in a new way that the flickering is non-perceptible and thus not hindering vision or causing discomfort. The firm was founded in 2018 and is based in Copenhagen, Denmark.
Cava Healthcare is focused on enhancing optimal health by predicting, preventing and alleviating diseases.
Cassava Sciences is clinical-stage biopharmaceutical company focused on neuroscience. It is based in Austin, Texas.
D&D Pharmatech is a healthcare holding company that develops therapeutics for dementia, Alzheimer's disease, and Parkinson's disease.
Disarm Therapeutics is developing therapeutics to treat patients with neurological diseases by preventing axonal degeneration. On October 15th, 2020, Disarm Therapeutics was acquired by Eli Lilly & Co at a valuation of $135M.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
